Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

How psychedelics without hallucinogenic effects may be effective for mental illness

Staff Writer
Staff Writer 2 years ago
Updated 2021/05/12 at 6:18 PM
Share
SHARE

In Cell Press, researchers at the University of California, Davis set out to develop psychedelic treatments for mental health problems without hallucinogenic effects.

Known as psychlight, the genetically encoded fluorescent sensor could establish hallucinogenic potential through the indication of serotonin 2A receptor activation. The serotonin 2A receptor, or 5-HT2AR, the target of psychedelic drugs.

“Here, we developed psychLight, a genetically encoded fluorescent sensor based on the 5-HT2AR structure. PsychLight detects behaviorally relevant serotonin release and correctly predicts the hallucinogenic behavioral effects of structurally similar 5-HT2AR ligands,” the study reads.

“We further used psychLight to identify a non-hallucinogenic psychedelic analog, which produced rapid-onset and long-lasting antidepressant-like effects after a single administration.”


The study concluded: “The advent of psychLight will enable in vivo detection of serotonin dynamics, early identification of designer drugs of abuse, and the development of 5-HT2AR-dependent non-hallucinogenic therapeutics.”

Photo: Shroomcircle

You Might Also Like

Machine learning research suggests drugs that may decrease cigarette smoking

New study explores test that can detect Alzheimer’s years before diagnosis

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

TAGGED: mental health, drugs, psychedelics
Staff Writer April 28, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Study examines how test anxiety can affect quality of sleep
Next Article Researchers probed the correlation between being partially sighted and dementia risk

Recommended

Health

Machine learning research suggests drugs that may decrease cigarette smoking

1 Min Read
Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?